Last 12 months
Inside the activity.
0 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 13, 2025 Filed Aug 14, 2025 16:01 UTC |
Quinlan James P.Chief Financial Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 125,000 | $0.00 Strike: $0.81 | $0.00 |
DisclosureSEC source: 0000950142-25-002189 · es250667851_4-quinlan.xml · derivative · entry 3 Quinlan James P. · CIK 0002047493 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 125,000 shares Expires 2028-10-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents an exercise price of $1.16 Canadian dollars, converted to U.S. dollars at the daily average exchange rate of $1.00 to CAD$1.4379 reported by the Bank of Canada on December 30, 2024. F3 · derivative.exercise_date: The option was vested and was exercisable as of the Transaction Date. Read SEC document |
| August 13, 2025 Filed Aug 14, 2025 16:01 UTC |
Quinlan James P.Chief Financial Officer
|
Exercise / conversionCommon Shares | 20,000 | $2.75 | $55,000.00 |
DisclosureSEC source: 0000950142-25-002189 · es250667851_4-quinlan.xml · nonDerivative · entry 2 Quinlan James P. · CIK 0002047493 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 274,147 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Represents an exercise price of $3.95 Canadian dollars, converted to U.S. dollars at the daily average exchange rate of $1.00 to CAD$1.4379 reported by the Bank of Canada on December 30, 2024. Read SEC document |
| August 13, 2025 Filed Aug 14, 2025 16:01 UTC |
Quinlan James P.Chief Financial Officer
|
Exercise / conversionCommon Shares, no par value ("Common Shares") | 125,000 | $0.81 | $101,250.00 |
DisclosureSEC source: 0000950142-25-002189 · es250667851_4-quinlan.xml · nonDerivative · entry 1 Quinlan James P. · CIK 0002047493 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 254,147 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents an exercise price of $1.16 Canadian dollars, converted to U.S. dollars at the daily average exchange rate of $1.00 to CAD$1.4379 reported by the Bank of Canada on December 30, 2024. Read SEC document |
| July 22, 2025 Filed Jul 24, 2025 21:19 UTC |
Raju AjayDirector · 10% owner
|
GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $3.08 | $0.00 |
DisclosureSEC source: 0000950142-25-002021 · es250658447_4-raju.xml · derivative · entry 1 Raju Ajay · CIK 0002049841 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Shares · 25,000 shares Expires 2030-07-22 F1 · derivative.exercise_date: The option was granted to Ajay Raju for his service as a director of the Company on July 22, 2025. The option is scheduled to vest quarterly in four equal installments over one year. Read SEC document |
| July 22, 2025 Filed Jul 24, 2025 21:15 UTC |
May Sara R.Director
|
GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $3.08 | $0.00 |
DisclosureSEC source: 0000950142-25-002017 · es250658443_4-may.xml · derivative · entry 2 May Sara R. · CIK 0002048946 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Shares · 25,000 shares Expires 2030-07-22 F3 · derivative.exercise_date: The option was granted on July 22, 2025. The option is scheduled to vest quarterly in four equal installments over one year. Read SEC document |
| July 22, 2025 Filed Jul 24, 2025 21:14 UTC |
Ciaruffoli Robert J.Director
|
GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $3.08 | $0.00 |
DisclosureSEC source: 0000950142-25-002014 · es250658439_4-ciaruffoli.xml · derivative · entry 2 Ciaruffoli Robert J. · CIK 0002048095 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Shares · 25,000 shares Expires 2030-07-22 F3 · derivative.exercise_date: The option was granted on July 22, 2025. The option is scheduled to vest quarterly in four equal installments over one year. Read SEC document |
| July 22, 2025 Filed Jul 24, 2025 21:16 UTC |
Mehmud FaisalChief Medical Officer
|
GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $3.08 | $0.00 |
DisclosureSEC source: 0000950142-25-002018 · es250658445_4-mehmud.xml · derivative · entry 2 Mehmud Faisal · CIK 0002047946 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Shares · 50,000 shares Expires 2030-07-22 F3 · derivative.exercise_date: The option was granted on July 22, 2025. The option is scheduled to vest quarterly in four equal installments over one year. Read SEC document |
| July 22, 2025 Filed Jul 24, 2025 21:13 UTC |
Brennan Edward J.Chief Scientific Officer
|
GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $3.08 | $0.00 |
DisclosureSEC source: 0000950142-25-002013 · es250658437_4-brennan.xml · derivative · entry 2 Brennan Edward J. · CIK 0002048104 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Shares · 50,000 shares Expires 2030-07-22 F3 · derivative.exercise_date: The option was granted on July 22, 2025. The option is scheduled to vest quarterly in four equal installments over one year. Read SEC document |
| July 22, 2025 Filed Jul 24, 2025 21:12 UTC |
Bonner Carolyn F.President
|
GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $3.08 | $0.00 |
DisclosureSEC source: 0000950142-25-002012 · es250658436_4-bonner.xml · derivative · entry 2 Bonner Carolyn F. · CIK 0002047487 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Shares · 50,000 shares Expires 2030-07-22 F3 · derivative.exercise_date: The option was granted on July 22, 2025. The option is scheduled to vest quarterly in four equal installments over one year. Read SEC document |
| July 22, 2025 Filed Jul 24, 2025 17:17 UTC |
Quinlan James P.Chief Financial Officer
|
GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $3.08 | $0.00 |
DisclosureSEC source: 0000950142-25-002019 · es250658446_4-quinlan.xml · derivative · entry 2 Quinlan James P. · CIK 0002047493 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Shares · 50,000 shares Expires 2030-07-22 F3 · derivative.exercise_date: The option was granted on July 22, 2025. The option is scheduled to vest quarterly in four equal installments over one year. Read SEC document |
| July 22, 2025 Filed Jul 24, 2025 21:15 UTC |
Kaiser LarryDirector
|
GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $3.08 | $0.00 |
DisclosureSEC source: 0000950142-25-002016 · es250658441_4-kaiser.xml · derivative · entry 2 Kaiser Larry · CIK 0002048184 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Shares · 25,000 shares Expires 2030-07-22 F3 · derivative.exercise_date: The option was granted on July 22, 2025. The option is scheduled to vest quarterly in four equal installments over one year. Read SEC document |
| July 22, 2025 Filed Jul 24, 2025 21:14 UTC |
FISHMAN BARRYDirector
|
GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $3.08 | $0.00 |
DisclosureSEC source: 0000950142-25-002015 · es250658440_4-fishman.xml · derivative · entry 2 FISHMAN BARRY · CIK 0001889532 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Shares · 25,000 shares Expires 2030-07-22 F3 · derivative.exercise_date: The option was granted on July 22, 2025. The option is scheduled to vest quarterly in four equal installments over one year. Read SEC document |
| July 22, 2025 Filed Jul 24, 2025 21:11 UTC |
Bokhari RazaDirector · Chief Executive Officer
|
GrantStock Option (right to buy) · Derivative | 250,000 | $0.00 Strike: $3.08 | $0.00 |
DisclosureSEC source: 0000950142-25-002011 · es250658435_4-bokhari.xml · derivative · entry 2 Bokhari Raza · CIK 0001660525 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Shares · 250,000 shares Expires 2030-07-22 F3 · derivative.exercise_date: The option was granted on July 22, 2025. The option is scheduled to vest quarterly in four equal installments over one year. Read SEC document |
| July 22, 2025 Filed Jul 24, 2025 21:10 UTC |
Ashton WilliamDirector
|
GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $3.08 | $0.00 |
DisclosureSEC source: 0000950142-25-002010 · es250658434_4-ashton.xml · derivative · entry 2 Ashton William · CIK 0001474553 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Shares · 25,000 shares Expires 2030-07-22 F3 · derivative.exercise_date: The option was granted on July 22, 2025. The option is scheduled to vest quarterly in four equal installments over one year. Read SEC document |
| May 20, 2025 Filed May 21, 2025 12:57 UTC |
VELOCITY FUND PARTNERS, LP10% owner
Melani Kenneth R.10% owner
|
SaleMedicus Pharma LTD | 75,000 | $7.72 | $578,940.00 |
DisclosureSEC source: 0001671948-25-000005 · primary_doc.xml · nonDerivative · entry 1 VELOCITY FUND PARTNERS, LP · CIK 0001671948 · 10% owner Melani Kenneth R. · CIK 0002050471 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 3,248,741 F1 · kind: The common shares were sold by Velocity Fund Partners, LP pursuant to an open market sale of 75,000 common shares on May 20, 2025 at a net price per common share of $7.7192. F2 · ownership.nature: Represents 2,839,330 common shares held by Velocity Fund Partners, LP an entity controlled by Dr. Kenneth R. Melani and 409,411 common shares held directly by Dr. Kenneth R. Melani. Dr. Kenneth R. Melani disclaims beneficial ownership of common shares held by Velocity Fund Partners, LP, except to the extent of his pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.